Rahul Pathak assists clients with intellectual property rights in the fields of chemistry and biochemistry. His practice includes patent prosecution and portfolio management, patent opinions, patent reexaminations and patent due diligence. Representative clients include start-up companies, established companies, leading life science companies, academic institutions, and investment firms in the pharmaceutical, biotechnology, renewable chemical, food and energy storage industries.

    During his legal career of more than 20 years, he has advised clients on developing and managing global patent portfolios for marketed pharmaceuticals and biopharmaceuticals, conducting intellectual property due diligence for private and public investments in pharmaceutical and biotechnology companies, and developing a patent portfolio of biofuels. Rahul holds a Ph.D. in chemistry and has extensive experience with small molecule therapeutics, therapeutic antibodies, antibody-drug conjugates, therapeutic peptides, therapeutic polypeptides, nucleic acid diagnostics, polypeptide biochemistry, structural biology and molecular biology. Dr. Pathak has contributed to patent protection for PEGASYS®, TYZEKA®, FOCALIN®, ZULRESSO™ and QBREXZA™, among other approved products.

    Rahul was named to the Daily Journal's 2015, 2014 and 2013 lists of Top 25 intellectual property portfolio managers in California – an annual list of the most highly regarded lawyers in the state who advise clients in the management of their IP portfolios or patent prosecutions.

    Rahul is a co-author of “Biofuels: A (Carbon) Balanced Act,” published in the San Diego Daily Transcript in 2008.

    Award Mouse thought multimedia interface book medal screen monitor
    • Representing a biotechnology company in the development and management of a patent portfolio related to nucleoside and non-nucleoside antiviral drugs.
    • Assisting a renewable products company with patent prosecution strategy and portfolio development regarding renewable biofuels and renewable chemicals.
    • Representing a pharmaceutical company with the development of an antibody-drug conjugate patent portfolio, including platform technology, modified amino acids, linkers, payloads and conjugates.
    • Representing a pharmaceutical company with the development of an antibody-drug conjugate patent portfolio, including novel antibodies, novel linkers, novel payloads and novel conjugates.
    • Assisting a pharmaceutical company with patent prosecution and portfolio management relating to small molecule oncological drugs.
    • Conducting successful ex parte reexaminations of patents related to a marketed small molecule pharmaceutical, a pharmaceutical drug candidate and a food product on behalf of the patent owners.
    • Defending merged inter partes reexamination of a patent related to safety glass on behalf of the patent owner.
    • Conducting inter partes reexamination of a patent related to a peptide therapeutic on behalf of a third party requester.

    Education

    • University of California, Berkeley, J.D., 1999
    • Yale University, B.Sc., Molecular Biophysics & Biochemistry, summa cum laude, 1991
    • California Institute of Technology, Ph.D., Chemistry, 1997

    Admissions

    • California, 2000
    • U.S. Patent and Trademark Office
    • Recognized in Chambers USA for Intellectual Property: Patent Prosecution in California
    • National Law Journal’s 2018 Intellectual Property Trailblazer

    {{insights.date}} {{insights.source}} {{insights.type}}
    {{blog.displayDate}}
    {{blog.title}} {{blog.source}}
    Award Mouse thought multimedia interface book medal screen monitor